Last Price
2.44
Today's Change
+0.36 (17.30%)
Day's Change
2.11 - 2.55
Trading Volume
22,233
Market Cap
3 Million
Shares Outstanding
1 Million
Avg Volume
17,495
Avg Price (50 Days)
3.45
Avg Price (200 Days)
11.82
PE Ratio
-0.01
EPS
-319.97
Earnings Announcement
12-Nov-2024
Previous Close
2.08
Open
2.17
Day's Range
2.11 - 2.55
Year Range
2.07 - 33.0
Trading Volume
22,233
1 Day Change
17.31%
5 Day Change
-1.61%
1 Month Change
7.02%
3 Month Change
-74.58%
6 Month Change
-85.73%
Ytd Change
-80.86%
1 Year Change
-86.66%
3 Year Change
-99.11%
5 Year Change
-99.65%
10 Year Change
-99.47%
Max Change
-99.90%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.